



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete If Known</b>		
			Application Number	10/732,847	
			Filing Date	December 9, 2003	
			First Named Inventor	John G. Gribben	
			Art Unit	1644	
			Examiner Name	P. Gambel	
Sheet	1	of	2	Attorney Docket Number	WYS-020.02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
PA	AA*	US-5,434,131	07-18-1995	Peter S. Linsley	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
PA	BA	WO-93/00431	01/1993			
	BB	WO-93/19767	10/1993			
	BC	WO-94/03202	02/1994			

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
PA	CA	KRUMMEL et al. J Exp Med 183: 2533-2540 (1996).			
	CB	BLUESTONE Immunity 2: 555-559 (1995).			
	CC	RUDIN et al. Curr. Opin. Hematol. 3: 35-40 (1996).			
	CD	YI-QUN et al. Intl. Immunol. 8: 37-44 (1996).			
	CE	BLAZAR et al. J. Immunol. 157: 3250-3259 (1996).			
	CF	KAHAN Curr. Opin. Immunol. 4: 553-560 (1992).			
	CG	GRIBBEN et al. PNAS 92: 811-815 (1995).			
	CH	WALUNAS et al. J Exp Med 183: 2541-2550 (1996).			
	CI	PERRIN et al. J. Neuroimmunology 65: 31-39 (1996).			
	CJ	PAUL (ED) Fundamental Immunology Raven Press NY 1993 p. 242.			
	CK	COYLE et al. Nature Immunology 2: 203-209 (2001).			
	CL	SKULNICK et al. Trends Biotech. 18: 34-39 (2000).			
	CM	Ngo et al. in the Protein Folding Problem and Tertiary Structure Prediction 1994 Merz et al. (ED) Birkhauser, Boston MA. pp. 433, 492-495.			
	CN	MUELLER Current Biology 10: 12227-12230 (2000).			
	CO	YANG et al. J. Exp. Med. 168: 1457-1468 (1988).			
	CP	LINDSTEN, T., et al., (1993) "Characterization CTLA-4 Structure and Expression on Human T Cells", The Journal of Immunology, vol. 151, No. 7, pp. 3489-3499.			
	CQ	HARPER, K., et al., (1991) "CTLA-4 and CD28 Activated Lymphocyte Molecules are Closely Related in Both Mouse and Human as to Sequence, Message Expression, Gene Structure, and Chromosomal Location", The Journal of Immunology, vol. 147, No. 3, pp. 1037-1044.			
	CR	JELLIS, C.L., et al., (1993) "Defining critical residues in the epitope for a HIV-neutralizing monoclonal antibody using phage display and peptide array technologies", Gene, vol. 137, pp. 63-68.			
	CS	LINSLEY, P.S., et al., (1992) "Coexpression and Functional Cooperation of CTLA-4 and CD28 on Activated T Lymphocytes", J. Exp. Med., vol. 176, pp. 1595-1604.			
CT	DARZYNKIEWICZ, Z., et al., (1992) "Features of Apoptotic Cells Measured by Flow Cytometry", Cytometry, vol. 13, pp. 795-808.				
CU	FREEMAN, G.J., et al., (1992) "CTLA-4 and CD28 mRNA are Coexpressed in most T Cells after Activation", The Journal of Immunology, vol. 149, No. 12, pp. 3795-3801.				

Examiner Signature	PAUL GAMBEL 10/1/07	Date Considered	
-----------------------	---------------------	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		<b>Complete if Known</b>	
		Application Number	10/732,847
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Filing Date	December 9, 2003
		First Named Inventor	John G. Gribben
		Art Unit	1644
		Examiner Name	P. Gambel
		Attorney Docket Number	WYS-020.02
Sheet	2	of	2


	CV	HARDIN, J.A., et al., (1992) "A simple fluorescence method for surface antigen phenotyping of lymphocytes undergoing DNA fragmentation", Journal of Immunological Methods, vol. 154, pp. 99-107.	
	CW	LINSLEY, P.S., et al., (1991) "CTLA-4 Is a Second Receptor for the B Cell Activation Antigen B7", J. Exp. Med., vol. 164, pp. 561-569.	
	CX	DARIAVACH, P., et al., (1988) "Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains", Eur. J. Immunol., vol. 18, pp. 1901-1905.	
	CY	BRUNET, Jean-Francois, et al., (1987) "A new member of the immunoglobulin superfamily--CTLA-4", Nature, vol. 328, pp. 267-270.	
	CZ	KUNTZ et al. Science 257: 1078-1082 (1992).	
	DA	NAGATA, S. et al., (1995) "The Fas Death Factor", Science, Vol. 267 pp.1449-1456.	
	DB	BOUSSIOTIS, V. et al., (1993) "Activated Human B Lymphocytes Express Three CTLA-4 Counterreceptors that Costimulate T-cell Activation", PNAS, Vol. 90, pp.11059-11063.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

*Paul P. Gambel 10/10/07*

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08a/b (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/732,847
				Filing Date	December 9, 2003
				First Named Inventor	John G. Gribben
				Art Unit	1644
				Examiner Name	P. Gambel
Sheet	1	of	1	Attorney Docket Number	WYS-020.02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PG	EA	Page, D. M. et al. Two signals are required for negative selection of CD4+CD8+ thymocytes. J Immunol. 1993 Aug 15;151(4):1868-80.	
PG	EB	Harding, F. A. et al. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 1992 Apr 16;356(6370):607-9.	
PG	EC	Freeman, G. J. et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science. 1993 Nov 5;262(5135):909-11.	
PG	EB	Hathcock, K. S. et al. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science. 1993 Nov 5;262(5135):905-7.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

*P. Gambel* 10/10/07

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--